+917069000000 anish.chandarana@cims.me

Expert in Angiography and Angioplasty

Top 10 Cardiologists in India

Dr. Anish Harjivandas Chandarana

M.D, D.M (Cardiology), FACC

Contact Details

Office Address Residence Address E-mail Phone
CIMS Hospital, Near Shukan Mall, Off. Science City Road, Sola Ahmedabad-380060. 21, Shyam Vihar Bunglows, Thaltej – Shilaj Road, Thaltej, Ahmedabad-380 059. anish.chandarana@cims.me +917930101100

Personal Details

Marital Status Spouse Children Nationality
Married Dr. Parvin A. Chandarana (Dentist) 1. Ritanshu (M)(23.08.01) 2. Mirra (F)(08.12.09) Indian

Educational Qualification

Exams Board/Uni. Passing Year Attempt Marks & Per(%) Remarks
D.M.(Cardio) Gujarat April 1999 First 586/1000 (58.6%) Uni. First-Gold Medalist
M.D.(Int. Medicine) Gujarat Nov. 1996 First 712/1000 (71.2%) Uni. First-Gold Medalist
Third M.B.B.S. Gujarat Dec. 1992 First 635/1000 (63.2%) Gynec & Obst.Gold Medalist
Second M.B.B.S. Gujarat Sept. 1991 First 377/600 (62.9%) –
First M.B.B.S. Gujarat Jan 1990 First 575/750 (76.7%) Uni. First-Gold Medalist
H.S.C.E. Gujarat Board March 1988 First 675/800 (84.0%) Eighth in Ahmedabad
S.S.C.E. Gujarat Board May 1986 First 610/700 (87.1%) –

Experience at Teaching Institute

  • Completed 3 years of M.D. residency in Internal Medicine department from January 1994 to January 1997 at Civil Hospital, Ahmedabad.
  • Completed 2 years of D.M. residency in Cardiology from January 1997 to January 1999 at the Institute of Cardiology and Research Centre, Ahmedabad.
  • Assistant Professor at Institute of Cardiology and Research Centre, Civil Hospital, Ahmedabad for more than 2 years from May 1999 to July 2001.
  • Attached to Sterling hospital, Ahmedabad as a Consultant and an Interventional Cardiologist from Oct 2001 to Feb 2004, and June 2009 to Aug 2010.
  • Attached to SAL Hospital, Ahmedabad as a consultant and Interventional Cardiologist from March 2004 to Oct 2009.

Former Affiliations as Cardiologist

  • U. N. Mehta Heart Institute, Civil Hospital, Ahmedabad.
  • Consultant and Interventional Cardiologist, Sterling Hospital, Ahmedabad.
  • Consultant and Interventional Cardiologist, S.A.L., Ahmedabad.

Present Affiliations as Cardiologist

  • CIMS Hospital, Ahmedabad.

Fellowship Residency

  • Internship: 1993: Civil Hospital, Ahmedabad.
  • Residency in Internal Medicine: 1994 to 1996: Civil Hospital, Ahmedabad.
  • Residency in Cardiology: 1997 to 1999: U. N. Mehta Heart Hospital, Institute of Cardiology and Research Centre, Ahmedabad.
  • Assistant Professor: 1999 to 2001: U. N. Mehta Heart Hospital, Institute of Cardiology and Research Centre, Ahmedabad.

Licensure

  • Gujarat Medical Council: G-21849, G-7368

Professional Experience

Interventional Cardiologist

  • @ Sterling Hospital, Ahmedabad: 2001 to 2004.
  • @ SAL Hospital, Ahmedabad: 2004 to 2010.
  • @ Apollo Hospital, Ahmedabad: 2004 to 2009.
  • @ CIMS Hospital: 2010 onwards.

Cardiac Interventions

  • Over 10,000 Cardiac Catheterizations including complex Coronary angiograms, valvular diseases, grafts, etc.
  • Over 4000 PTCA /Angioplasties including complex. Multivessel grafts, etc.
  • Over 800 cases in Primary/Rescue Angioplasties.
  • Over 3000 stents used.
  • Over 500 Balloon Mitral Valvuloplasties.
  • Over 50 Other valvular interventions.

Peripheral Interventions

  • Over 100 cases of Peripheral Interventions.
  • Over 200 cases of Peripheral Diagnostic Angiography.
  • Over 50 Percutaneous Intra vascular Stenting.
  • Over 50 Pacemaker implantation.

Clinical Experience

  • Performed as well as actively participated in various noninvasive and invasive cardiological procedures in addition to clinical examination and evaluation of patients.
Sr. No. Procedures No. of Procedures performed / participated (approx)
1 2D Echocardiography and Color Doppler examination 25000
2 Tread Mill test 5000
3 Holter ECG monitoring 500
4 Pericardial tapping 100
5 Temporary pacing 250
6 Permanent pacing (single & dual chamber) 150
7 Coronary angiography 5000
8 Peripheral angiography and aortogram 500
9 Percutaneous Transluminal Coronary Angioplasty/Stenting 2000
10 Percutaneous peripheral / renal angioplasty 200
11 A-Percutaneous balloon mitral valvuloplasty 800
B-Percutaneous commissurotomy 30
12 Percutaneous balloon aortic valvuloplasty 50
13 Percutaneous balloon pulmonary valvuloplasty 50
14 Percutaneous balloon coarctation dilatation 20
15 Percutaneous PDA coil closure / Aveplatzer device closure 100
16 Percutaneous ASD device closure 20

Research Work & Publications

  1. A Dissertation submitted to Gujarat University for M.D (Internal Medicine) examination held in March 1996.

Topic: Paraplegia: A study of 30 patients with MRI.

2.  A Dissertation submitted to Gujarat University for D.M. Cardiology examinations held in March 1999.

Topic: Multi-vessel coronary intervention: immediate results and short-term follow-up.

  • Scientific papers published in the 49th Annual Conference of The Cardiological Society of India, November 1997. Abstract issue- Indian Heart Journal. Vol. 49, No.6.
    • Concurrent multivalent balloon dilatation: Acute results and short-term follow up. Shah U.G., Dani S.I., Shah B.R., Rawal J.R., Jain S.S., Chandarana A.H., Joshi H.U.
    • Permanent pacemaker implantation in Gujarat: A single centre experience. Dani S.I., Mehta S.K., Rawal J.R., Shah B.R., Prajapati J., Chandarana A.H., Joshi H.U.
    • Left main coronary artery disease in Gujarati population. Dani S.I., Chandarana A.H., Rawal J.R., Shah B.R., Shah U.G., Jain S.S, Baxi H.B, Joshi H.U.
    • Pulmonary Stenosis: Long term results of balloon dilatation. Dani S.I., Rawal J.R., Shah B.R., Jain S.S., Shah U.G., Baxi H.B., Chandarana A.H., Joshi H.U.
  • Scientific papers published in the 50th Annual Conference of The Cardiological Society of India, December 1998. Abstract issue- Indian Heart Journal, Vol.50, No.6.
    • Balloon dilatation of coarctation of aorta in adults: immediate results and intermediate follow up. Dani S.I., Rawal J.R., Shah B.R., Jain S.S., Shah U.G., Baxi H.B., Chandarana A.H., Joshi H.U.
    • Combination of plain PTCA with stenting in coronary artery disease: immediate and intermediate-term outcome. Dani S.I., Shah B.R., Shah U.G., Baxi H.B., Chandarana A.H., Joshi H.U.
    • Pura Vario- A poor man’s stent: Six months clinical and angiographic follow up. Solanki D.R., Dani S.I., Shah B.R., Shah U.G., Jain S.R., Chandarana A.H.
    • Intracoronary Saint Come stents: Short and mid-term follow up results.Shah B.R., Dani S.I., Shah U.G., Jain S.R., Chandarana A.H., Baxi H.B.
  • Scientific paper published in the 54th Annual conference of Cardiological Society of India, December 2002. Abstract: Indian Heart Journal. Distal Protection Device Percusurge guardwire: Use in native coronary arteries in setting of Acute Coronary Syndrome.
  • Comparison between different LMWH: Are they different? An article published in the Annual Journal of Associations of Physicians of Gujarat, December 2002.
  • JNC VII guidelines for prevention, detection, evaluation and treatment of Hypertension: An Indian perspective An article published in the Annual Journal of Associations of Physicians of Gujarat, December 2003.
  • Reversal of Slow or no-reflow During Percutaneous Transluminal Coronary Angioplasty Using Boluses of Intracoronary Adenosine and Sodium Nitroprusside in Combination. Journal of American College of Cardiology (Supplement A) March 19, 2003; Vol 41: Issue 6: 1101-201. Parikh K.H., Chag M.C., Shah U.G., Baxi H.B., Chandarana A.H., Naik A.M., Shah k. J., Goyal R.K.
  • Effect of Folate treatment on Homocysteinemia in Cardiac patients: A Prospective Study. Indian J Cardiol 2002; ISSN 0972 – 1622 Vol 5: No. 1-4: 53. Mehta K.N., Parikh K.H., Chag M.C., Shah U.G., Baxi H.B., Chandarana A.H., Naik A.M., Goyal R.K.
  • Reversal of Slow or no- reflow During Percutaneous Transluminal Coronary Angioplasty Using Boluses of Intracoronary Adenosine and Sodium Nitroprusside in Combination. Indian J Cardiol 2003, 5: 38. Shah K. J., Parikh K.H., Chag M.C., Shah U.G., Baxi H.B., Chandarana A.H., Naik A.M., Goyal R.K.
  • Effect of Folate treatment on Homocysteinemia in Cardiac patients: A Prospective Study. Pharmacological Research (Submitted). Mehta K.N., Parikh K.H., Chag M.C., Shah U.G., Baxi H.B., Chandarana A.H., Naik A.M., Goyal R.K.
  • Acute Results of Intermediate – Term follow up of Percutaneous Transluminal Coronary Angioplasty with Cardioprotection by balloon Occlusion Distal Protection Device. Indian Heart J, J-233 2002; 54: 561- 568. Parikh K.H., Chag M.C., Shah U.G., baxi H.B., Chandarana A.H., naik A.M., Goyal R.K., Shah K.J.
  • Prevalence of hyperhomocysteinemia in Western Indian Population with or without Coronary Artery Disease. Indian J Cardiol. (In Press). Shah K.J., Parikh K.H., Chag M.C., Shah U.G., Baxi H.B., Chandarana A.H., Naik A.M., Goyal R.K.
  • Effect of Folate Treatment on Homocysteinemia in Cardiac Patients: A Prospective Study: Mehta K.N., Parikh K.H., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik AM, Goyal R.K. Indian J Pharmacol. (Abstract)
  • Acute results and Intermediate term follow up of PCI with Cardioprotection by Balloon Occlusion Distal Protection Device. Parikh K.H., Chag M.C, Shah U.G, Baxi H.A., Chandarana A.H., Naik A.M, Goyal R.K., Shah K.J. Indian Heart J. J-233, 2002; 54: 561-568.
  • Effect of Folate Treatment on Pharmacological Homocysteinemia in Cardiac Research Patients: A Prospective Study. Mehta K.N., Parikh K.H., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M., Goyal R.K. Pharmacological Research (submitted) 2003.
  • Effect of Folate Treatment on Homocysteinemia in Patients: A Prospective Study. Mehta K.N., Parikh K.H., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M., Goyal R.K. Indian J Cardiol.2003; 5: 53.
  • Reversal of Slow-Flow or No-Reflow in PTCA using boluses of IC Adenosine and Sodium Nitroprusside combination. Shah K.J., Parikh K.H., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M., Goyal R.K. Indian J Cardiol. 2003: 5: 38.
  • Reversal of Slow-Flow or No-Reflow in PTCA using Boluses of IC Adenosine and Sodium Nitroprusside. Parikh K.H., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M.,Shah K.J., Goyal R.K. Suppl to JACC, March 19, 2003; 41 (6), Suppl A: 1101- 201.
  • First in Human Implanted Device in Pulmonary Artery Using Acoustic Telemetry Based on Non-Invasive Ultrasound Activation and Communication. Parikh KH, Shah HD, Naik AM, Chag MC, Shah UG, Baxi HA, Chandarana AH, Shah JN, Rozenman Y, Waagstein F*, Hjalmarson A*. Accepted in ACC 2006.
  • Effect of Metoprolol CR/XL on Pulmonary Artery Pressure in Heart Failure measured non-invasively using first-in-man implantable device responding to ultrasonic signal. Parikh KH, Shah HD, Naik AM, Chag MC, Shah UG, Baxi HA, Chandarana AH, Shah JN, Rozenman Y, Waagstein F*, Hjalmarson A*. Accepted in ACC 2006.
  • Effect Of Metoprolol CR/XL On Diurnal Variation In Pulmonary Artery Pressure Measured Non-invasively Using First In Human Implant Responding To Ultrasonic Signals. Parikh KH, Shah HD, Naik AM, Chag MC, Shah UG, Baxi HA, Chandarana AH, Shah JN, Rozenman Y, Waagstein F*, Hjalmarson A*. Accepted in ACC 2006.

Current Affiliation

  • Executive Director, Care Institute of Medical Sciences, Ahmedabad, India.
  • Director, Clinical Care Consultant Pvt Ltd Ahmedabad, India.
  • Consultant and Interventional Cardiologist at CIMS Hospital, Ahmedabad, India.

Affiliations So Far

  • SAL Hospital & Medical Institute, Ahmedabad.
  • Sterling Hospital, Ahmedabad.
  • Krishna Heart institute, Ahmedabad.
  • Sheth V.S. General Hospital, Ahmedabad.
  • Apollo Hospital (Gandhinagar), Ahmedabad.
  • Care Institute of Medical Sciences, Ahmedabad.

Conferences Attended

  • Cardiology Society of India, Annual conference: 1998, 1999, 2000, 2002, 2007.
  • Joint Interventional Meet, Roma, Italy, February 2002.
  • PTCA Registry, 2001, Kochi, Kerala India.
  • Indofrench meet, 2001, Hyderabad, India.
  • TCT, Washington DC, 2003, USA.
  • Uro PCR, 2004, Paris, France.
  • European Society of Cardiology, 2006 Spain.
  • European Society of Cardiology, 2007 Spain.
  • World Heart Congress,2007 Spain.
  • European Society of Cardiology Conference,2010 Sweden.

Professional Membership

  • Life member of CSI (Cardiac Society of India)
  • Life member of IMA (Indian Medical Association)

Teaching Experience & Seminars

Conducted Teaching Seminars and Conferences as a Faculty/ Expert.

  • Symposium and Update in Cardiovascular Disease.
  • Comprehensive ECG, Arrhythmia & Electro- Physiology Course.
  • Comprehensive Echocardiography Course.
  • Updates in Congenital Heart Diseases.
  • Cardio- Pulmonary Resuscitation and Critical care.
  • Has delivered more than 1000 lectures in different group of doctors like different IMA branches, MBBS, MD. In Gujarat, Rajasthan, M.P and other parts of the country.
  • Has delivered more than 200 lectures for health awareness to community.

Clinical Research Accomplished

Conducted Teaching Seminars and Conferences as a Faculty/ Expert.

  • Effect of Folate treatment on Homocysteinemia in cardiac patients: A Prospective Study.
  • Pharmacoepidemiology and Risk factors of Hypertension in Gujarat.
  • Reversal of slow or no- reflow During Percutaneous Transluminal Coronary Angioplasty Using Boluses of Intracoronary Adenosine and Sodium Nitroprusside in combination.
  • Acute Results of Intermediate – term follow up of Percutaneous Transluminal Coronary Angioplasty with Cardioprotection by Balloon Occlusion Distal Protection Device.
  • Effect of Tirofiban HCl in Patients with Acute Coronary Syndrome and its comparison with other GPIIb/IIIa antagonists such as Abciximab and Eptifibatide.
  • Revascularization Utilizing Balloon Protection in Acute Coronary ischemic Syndrome- An International Registry.
  • An International Registry of CYPHER TM-Sirolimus eluting stent.
  • High prevalence of Renal Artery Stenosis in Hypertensive patients with Triple vessel Coronary Artery Disease.
  • Effects of Combination of Statins and Fenofibrates with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention.
  • Effect of Pioglitazone and its combination with Statins in Coronary Artery Disease patients with Hsyperinsulinemia.
  • Comparison of Drug eluting stent with S7 stent.
  • Assessment of Risk factors for Coronary Artery Disease.
  • Effect of Niacin treatment on hyperlipoproteinemia in Coronary Artery Disease patients.
  • Beneficial effects of Distal Protection Device in reducing the use of Intracoronary Vasodilators and Glycoprotein IIb/IIIa receptor antagonists during Percutaneous Coronary Interventions.
  • Comparison of Total Procedural time involved in Primary PCI with or without the use of Distal Balloon Protection system in Thrombotic Coronary lesions. (RAPID trial- Revascularization in Acute myocardial infarction using Percusurge In Distal protection).

International Clinical Trials

1

 Co – Investigator for RUBY registry (For India) (2002) To evaluate Percusurge / Guardwire Distal Protection Device (Presented by Dr. Aman, Switzerland)

Trial completed

2

 Co – Investigator at Sterling Hospital for Extract-TIMI 25 Multicentre multinational Trial (2003) Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction – Study 25.

Trial completed

3

 Co – Investigator for  OASIS-5 Trial (2004) To evaluate the efficacy and safety of fondaparinux versus Enoxaparin in the acute treatment of  unstable angina or non ST-segment elevation myocardial infarction acute coronary syndromes.

Trial completed

4

 Co – Investigator for  OASIS-6 Trial (2004) To evaluate the efficacy and safety of fondaparinux sodium versus control therapy and Glucose-Insulin-Potassium infusion versus control in broad range in patients with ST – segment elevation acute myocardial infarction.

Trial completed

5

 Co – Investigator for TRUST Trial (2004) To evaluate the safety and efficacy of intravenous Remodulin® in patients( in India) With Pulmonary arterial hypertension (PAH) in 12-week.

Trial completed

6

 Co – Investigator for Paediatric Hypertension Trial (2005) Dose ranging study to evaluate the  safety and efficacy of Olmesartan medoxomil in children and adolescents with hypertension.

Trial completed

7

 Co – Investigator for Hypercholesterol study (NK-104-301) at The Heart Care Clinic (2005) Study of Pitavastatin 2 mg vs. Atorvastatin 10 mg and Pitavastatin 4 mg vs. Atorvastatin 20 mg (Following Up Titration) in Patients with Primary Hypercholesterolemia Or Combined Dyslipidemia.

Trial completed

8

 Co – Investigator for Neovasc Reducer™ Pilot Study, First in human: (2005) To evaluate the safety of the Neovasc Reducer™ in the treatment of Ischemic heart Disease (IHD), controlled narrowing of the coronary sinus.

Trial completed

9

 Co – Investigator For PAPIRUS Trial: Pilot Study, First in Human: Apollo Hospital (2005) Monitoring Pulmonary Artery Pressure by Implantable Device Responding to Ultrasonic Signal(REMON Device)

Trial completed

10

 Co – Investigator for Export study (2006) Flow improvement in patients with Acute Myocardial Infarction undergoing either conventional stenting or a strategy of primary aspiration followed by stenting using the Export® Aspiration Catheter: a Prospective, Randomized, Controlled Study.

Trial completed

11

 Co – Investigator for E-five registry (for India) (2006) To Evaluate the ‘Real World’ Clinical Performance of the Medtronic Endeavor™ ABT-578 Eluting Coronary Stent System.

Trial completed

12

 Co – Investigator for RELY study (2006) Randomized Evaluation of Long term anticoagulant therapycomparing efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, Parallel group, non-inferiority trial.

Trial completed

13

 Co – Investigator for Hypercholesterolemia study (NK-104-307) at The Heart Care Clinic (2006) Open label, long-Term (1year) extension study of Pitavastatin 4 mg QD in patients with Primary Hypercholesterolemia or combined Dyslipidemia.

Trial completed

14

 Co – Investigator for  e-SELECT Registry (2007) The e-SELECT Registry: A Multicenter Post Marketing Survelliance.

 Trial completed

15

 Co – Investigator for Early ACS trial (2007) Early Glycoprotein Iib/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded  Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS)

Trial completed

16

 Principal  – Investigator  for PLATO trial (2007) A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and safety study of AZD6140 Compares with Clopidogrel for prevention of Vascular Events in patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO – A study of PLATelet inhibition and Patient Outcomes.]

Trial completed

17

 Co – Investigator  for OASIS- 7 trial (2007) Randomized, multinational, double-blind study, comparing a high loading dose regimen of Clopidogrel versus standard dose in patients with unstable angina or non-ST segment elevation myocardial infarction managed with an early invasive strategy.

Trial completed

18

 Co – Investigator  for New Guidewire (2007) First in Man: A Feasibility study to evaluate safety and efficacy of New Guidewire for Crossing Total Occlusions in Coronary Arteries.

Trial completed

19

 Co – Investigator for Paediatric Hypertension Trial, The Heart Care Clinic, Ahmedabad (2007) A Randomized, double blind, Placebo-Controlled, Multicenter, Parallel Study Assessing the Efficacy, Safety, and Dose Response of Ramipril for the Treatment of Hypertension in Children and Adolescents.

Trial completed

20

 Co – Investigator for Aristotle Trial at The Heart Care Clinic, Ahmedabad (2007) Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation: Active controlled randomized double blind parallel  arm study to evaluate efficacy and safety of Apixaban in subject with  non valvular Atrial fibrillation.

Follow-ups ongoing

21

 Co – Investigator for Rocket Trial at The Heart Care Clinic, Ahmedabad (2007) Multicenter, Randomized, double-blind – dummy, Parallel-group, Non-inferiority Trial Comparing the Efficacy and Safety of Once-daily oral Rivaroxabab (BAY 59-7939) with Adjusted-dose oral Warfarin for the prevention of Stroke and Non-central-nervous-system systemic embolism in Subjects with Non-valvular Atrial Fibrillation.

Follow-ups ongoing

22

 Co – Investigator  for PROTECT Trial (2007) Patient Related Outcomes with Endeavor versus Cypher stenting Trial: Prospective, multicenter, randomized, two-arm, open-label trial.

Follow-ups ongoing

23

 Co – Investigator  for TMC-CAN-05-02 (2007) A clinical trial comparing Cangrelor to Clopidogrel in subject who require Percutaneous Coronary Intervention.

Follow-ups ongoing

24

 Co – Investigator  for TMC-CAN-05-03 (2008) A clinical Trial comparing treatment with Cangrelor (in combination with usual care) to usual care in subjects who require Percutaneous Coronary Intervention.

Follow-ups ongoing

25

 Co – Investigator  for CL  (Ivabradine) at The Heart Care Clinic (2008) Evaluation of the anti-anginal efficacy.

Follow-ups ongoing

26

 Co – Investigator  for  RE-DEEM at The Heart Care Clinic (2008) Randomized Dabigatran Etexilate dose finding study in patients with acute coronary syndromes post index Event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel: Multi-centre, prospective, placebo controlled, group dose escalation trial.

Trial completed

27

 Co – Investigator for Magellan Trial (2008) A Multicenter, Randomized, parallel-group efficacy superiority study in hospitalize medically ill patients comparing rivaroxaban with Enoxaparin.

Follow-ups ongoing

28

 Co – Investigator for Borealis Trial at The Heart Care Clinic Ahmedabad (2008) A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjusted-dose warfarin in the prevention of stroke and systemic thromboembolic events in patient with atrial fibrillation.

Trial completed

29

 Co – Investigator  for Freedom-PAH at The Heart Care Clinic FREEDOM UT – 15C Studies (TDE-PH-302 and TDE-PH-304) conducted by United Therapeutics.

Ongoing

30

 Co – Investigator  for ORBIT – 1 Pilot study to evaluate the safety & performance or the diamond back 360TM orbit Atherectomy system in treating de-NOVO calcified coronary lesions – orbit -1.

Trial completed

31

 Co – Investigator for AVERROES at The Heart Care Clinic CV 185-048: A Phase 3, Active (Aspirin) Controlled, Randomized, Double-Blind, Parallel arm Study to Evaluate the Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation.

Trial completed

32

 Co – Investigator  for Red-HF at The Heart Care Clinic A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction  and Anemia – 20050222 Amendment 1.

Ongoing

33.

 Co – Investigator  for TAK-442-202 at The Heart Care Clinic A Phase II, double-blind, Randomized, Placebo-controlled study of the safety and Efficacy of TAK-442 in subjects with Acute Coronary Syndrome.

Trial completed

34.

 Co – Investigator  for EISAI-202 at The Heart Care Clinic A Randomized, Double-Blind Placebo controlled study of the safety and tolerability of E5555 and its effect on clinical event and biomarkers in patient with Non ST segment Elevation Acute Coronary Syndrome.

Trial completed

35

 Co – Investigator for E-Resolute at the Heart Care Clinic Evaluation of the Endeavor Resolute Zolarolumes-Eluting Coronary Stent System in a ‘Real World’ Patient Population.

Follow-up ongoing

36

 Co – Investigator  of RIVAROXABAN at The Heart Care Clinic Randomized, Double Blind, Placebo Controlled, Event Driven, Multi Center Study To Evaluate The Efficacy And Safety Of Rivaroxaban In Subjects With Recent ACS.

Follow-up ongoing

37

 Co – Investigator of Pfizer PAH at The Heart Care Clinic B1321001 A Phase 3, Multi Center, Randomized, Double Blind, Placebo Controlled, Safety And Efficacy Study Of Sitaxsentan Sodium In Subjects With Pulmonary Arterial Hypertension.

Ongoing

38

 Co – Investigator  of Pfizer PAH at The Heart Care Clinic B1321002 A Phase 3, Multi Center, Open Label Study To Evaluate The Long Term Safety Of Monotherapy Sitaxsentan Sodium And Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension.

Ongoing

39

 Co – Investigator of Pfizer PAH at The Heart Care Clinic B1321003 A Phase 3, Multi Center, Randomized, Double Blind, Efficacy And Safety Study Of Monotherapy Sitaxsentan Sodium Versus Combination Therapy With Sitaxsentan Sodium and Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension Who Have Completed Study B1321001.

Ongoing

40

 Co – Investigator  of LPL STABILITY at The Heart Care Clinic A Clinical Outcome Study Of Darapladib Versus Placebo In Subjects With Chronic Coronary Heart Disease To Compare The Incidence Of Major Adverse Cardiovascular Event. (MACE)

Follow-up ongoing

41

 Co – Investigator  of OASIS-8 at The Heart Care Clinic A Prospective Study Evaluating The Safety Of Two Regimens Of Adjustive Intravenous UFH PCI In High Risk Patients With UA/NSTEMI Initially Treated With Subcutaneous Fondaparinux And Referred For Early Coronary Angiography.

Follow-up ongoing

42

 Co – Investigator of STEM CELL A Randomized, Double Blind, Multi Centric, Placebo Controlled, Single Dose, Phase I/II Study Assessing The Safety And Efficacy Of Intravenous Ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cell In Patients With ST Elevated Acute MI  (STEMI) Patient.

Follow-up ongoing

44

 Co – Investigator  for RUBY 1 Trial at The Heart Care Clinic Ahmedabad (2010) A Randomized, Double Blind, Placebo Controlled, Multi Center and Parallel Group Study of the Safety, Tolerability, and Efficacy of YM150 in combination with  Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects with Acute Coronary Syndromes.

Follow-up ongoing

45

 Co – Investigator  for AmarinTrial at The Heart Care Clinic Ahmedabad (2010) A phase 3, multicenter, placebo controlled, randomized, double blind, 12 week study with an open label extension to evaluate the efficacy And safety of AMR101 in patients with fasting triglyceride levels > 500 mg/dl and < 2000 mg/dl.

Follow-up ongoing

46

 Co – Investigator  for SASHF RTrial at The Heart Care Clinic Ahmedabad (2008) South Asian Systolic Heart Failure Registry.

Ongoing

47

 Co – Investigator   for TRAC HF Trial at The Heart Care Clinic Ahmedabad (2009) TRAC HF: Ambulatory Monitoring Using External Physiological Sensors in Heart Failure Patients.

Ongoing

48

 Co – Investigator for Alecardio trial at CIMS hospital Cardiovascular outcomes study  to evaluate the potential of aleglitazar  to reduce reduce  cardiovascular  risk in patients with  recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)

Ongoing

49

 Co – Investigator for Timi 52 trial at CIMS hospital A Clinical Outcomes Study of Darapaladib versus Pleacebo in Subjects Following  Acute Coronary Syndrome  to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)

Ongoing

50

 Co – Investigator for Resolute Asia trial at CIMS hospital Evaluation of the Endevor Resolute Zotarolimus-Eluting Coronary Stent System in a Patient Population with Long Lesion(s) aand/or Dual Vessels in Asia; Prospective, Multi-center, Non-randomized Study.

Ongoing

51

 Co – Investigator for Appraise-2 trial A Phase 3, Randomized, Double-blind, Evaluation of the safety and Efficacy of Apixaban in subjects with a Recent Acute Coronary Syndrome.

Follow-up ongoing

National Clinical Trials
1 Co – Investigator for BIVAFLO Registy (2006) To evaluate the efficacy and safety of BIVAFLO® as an adjunctive therapy during PCI in moderate-high risk ACS patients with provisional GP IIb/IIIa inhibitors use. Trial completed
2 Co – Investigator for CORREL + C Trial (2006) The COREL C Registry: A multicentre Post marketing Survelliance for clinical and angiographic evaluation of Corel C stent. Trial completed
3 Principal Investigator for POLYCAP Trial at VS hospital Ahmedabad(2007) A randomized double blind controlled trial of the efficacy And safety of POLYCAP Vs its components in subjects With atleast one additional cardiovascular risk factor. Trial completed
4 Co – Investigator for ACUNOVA Trial (2006-2007) A phase III, open label, multicentric, parallel group, Randomized study to evaluate the safety and efficacy of Abciximab in Indian patients scheduled for Percutaneuos Coronary Intervention. Trial completed
5 Co – Investigator for ZYHI Trial at The Heart Care Clinic Ahmedabad (2007). (1) A randomized, double blind parallel group, prospective dose ranging study of ZYH 1 with an open fenofibrate arm to evaluate the efficacy on dyslipidemia in patients without diabetes Protocol No. 2001 Ver: 01 (2) A randomized, double blind parallel group, prospective dose ranging study of ZYH1 with an open pioglitazone arm to evaluate the efficacy on dyslipidemia in patients with diabetes Protocol No. 2003 Ver: 02 (3) A randomized, double blind parallel group, prospective dose ranging study of ZYH 1 with an open pioglitazone arm to evaluate the efficacy on dyslipidemia in patients with impaired glucose test Protocol No.2004 Ver: 02. Trial completed
Dr. Anish Chandarana, MD, DM (Cardiology, Gold Medalist) – Senior Cardiologist at CIMS Hospital in Ahmedabad, Gujarat, India +91 9825096922.
Based on the above merits, accomplishments, and detailed resume, as well as from patient feedback across many years, Dr. Anish Chandarana is considered as one of the best cardiologists in Ahmedabad, Gujarat and India.